Yale Study Reveals GSK3β Inhibitors as Promising Treatment for Relapsed B-Cell Acute Lymphoblastic Leukemia
Key Insights
Yale researchers discovered that B-cell acute lymphoblastic leukemia (search) cells have a unique vulnerability to β-catenin (search) accumulation, unlike other cancers that typically have high β-catenin levels.
The study found that GSK3β inhibitors (search), originally developed for Alzheimer's and Parkinson's diseases, effectively kill B-ALL (search) cells by disrupting their β-catenin (search) clearance mechanism.
Patient-derived xenograft models showed that GSK3β inhibitors (search) overcame conventional drug resistance and eradicated B-ALL (search) cells at lower concentrations than previously tested doses.
A Yale-led study has identified a novel therapeutic vulnerability in B-cell acute lymphoblastic leukemia (search) (B-ALL (search)), revealing that existing drugs developed for neurological diseases could offer new hope for patients with relapsed leukemia. The research, published January 8 in Nature Cancer, demonstrates that B-ALL cells are uniquely sensitive to disruption of their β-catenin (search) protein clearance mechanism.
Unique β-Catenin Vulnerability in B-ALL
The study uncovered an unusual characteristic of B-ALL (search) that distinguishes it from most other cancers. While solid tumors typically have high levels of β-catenin (search) protein due to oncogenic mutations that disrupt degradation machinery, B-ALL cells maintain intact β-catenin degradation pathways and express markedly lower β-catenin protein levels.
"Because B-ALL (search) cells are extremely sensitive to β-catenin (search) accumulation, we tested if disrupting the β-catenin protein removal machinery can overcome drug resistance and prevent relapse in B-ALL," says senior author Markus Müschen, MD, PhD, director of Yale's Center of Molecular and Cellular Oncology (search) and Arthur H. and Isabel Bunker Professor of Internal Medicine (Hematology) at Yale School of Medicine.
The research revealed that β-catenin (search) protein in B-ALL (search) is constitutively phosphorylated by glycogen synthase kinase 3 beta (search) (GSK3β (search)) and primed for proteasomal degradation. This high-efficiency clearance mechanism keeps β-catenin barely detectable in B-ALL cells, where it is immediately removed by an efficient clearance mechanism.
Altered Cellular Mechanisms Drive Therapeutic Opportunity
Unlike in solid tumors where β-catenin (search) forms transcriptionally active complexes with T cell factor to activate MYC-dependent transcription, B-ALL (search) cells utilize a fundamentally different mechanism. In these leukemia cells, β-catenin interacts with B lymphoid Ikaros and nucleosome remodeling and deacetylase complex factors, resulting in repression of MYC expression.
When β-catenin (search) degradation is disrupted, this leads to acute cell death in B-ALL (search) cells. CRISPR screening approaches confirmed that β-catenin protein degradation represents a central mechanistic target of established GSK3β inhibitors (search), providing genetic validation for the therapeutic approach.
Clinical Translation and Drug Repurposing
The researchers evaluated GSK3β (search) inhibition using patient-derived xenograft models, including samples from patients with B-ALL (search) relapse. The results demonstrated that GSK3β inhibitors (search) effectively induced B-ALL cell death and overcame conventional drug resistance.
Importantly, the study found that GSK3β inhibitors (search) eradicated B-ALL (search) cells at much lower concentrations than the doses used in previous clinical trials for neurological diseases, forecasting lower side effects and greater efficacy in B-ALL treatment.
Several GSK3β inhibitors (search) have already demonstrated favorable safety profiles in multiple clinical trials for Alzheimer's and Parkinson's diseases, where they were found to be safe and well-tolerated by patients. This existing safety data provides a significant advantage for potential clinical translation.
Addressing Unmet Medical Need
While treatment of B-ALL (search) has improved markedly in recent years, children and teenagers who relapse with the disease still face poor outcomes. Even those who are considered cured often experience long-term side effects from toxic high-dose chemotherapy treatments, including problems with their hearts, central nervous systems, and bone growth.
"Since several GSK3β (search)-inhibitors achieved favorable safety profiles in clinical trials, our results provide a rationale for repurposing these drugs for patients with refractory B-cell malignancies," says Müschen, who leads the international study consortium.
International Research Collaboration
This international research effort includes 10 scientists at Yale University and the Müschen Laboratory at Yale School of Medicine, as well as clinicians and scientists affiliated with research centers, universities, and hospitals in Boston, San Francisco, Los Angeles, Freiburg, Munich, Oslo, and Kyoto.
The research was supported by the National Institutes of Health, Yale University, the V Foundation for Cancer Research, Blood Cancer United, the Howard Hughes Medical Institute, German Cancer Aid, and the German Research Foundation.